Patient Selection Criteria for Pilot Studies on Amelioration of Non-Neovascular Age-Related Macular Degeneration
Open Access
- 24 July 2010
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 26 (4) , 367-371
Abstract
Purposes: Non-neovascular age-related macular degeneration (AMD) is characterized by accumulation of macular drusen, changes in pigmentation of the retinal pigment epithelium, and geographic atrophy. The purposes of this study were to (1) measure the rate of progression of non-neovascular AMD and (2) from the rate data, to propose patient selection criteria for testing drugs to prevent progression of non-neovascular AMD. Methods: Medical charts were searched for all AMD billing codes, consecutively reviewed, and 51 patients with a median age of 76 years were mined for severity of AMD using a standardized worsening scale from 0 to 6, visual acuity (VA, Snellen), medications or procedures to treat eye diseases, date of eye examinations, age, and sex. Individual eyes, excluding those with cataract, were grouped and compared. Results: Using all grades, VA (logMAR) was positively correlated with AMD scores ( P < 0.0001, n = 66). The median length of time to progress from AMD grade 3 or 4 to the next grade was 1.0 ( n = 14) and 1.7 years ( n = 7), respectively. Statistical analyses predicted that drug-treated and nontreated groups, each containing 409 grade 3 and 4 AMD eyes, could detect 50% drug inhibition ( P = 0.05) in a 2-year trial. Conclusions: VA measurements and structural AMD grades would be useful markers in clinical trials on non-neovascular AMD. Recruiting only grade 3 and 4 patients may be ideal for time- and cost-efficient pilot drug efficacy studies on moderately progressing non-neovascular AMD.Keywords
This publication has 10 references indexed in Scilit:
- Calpain Inhibitor SNJ-1945 Attenuates Events Prior to Angiogenesis in Cultured Human Retinal Endothelial CellsJournal of Ocular Pharmacology and Therapeutics, 2009
- The Role of Calcium-Activated Protease Calpain in Experimental Retinal PathologySurvey of Ophthalmology, 2008
- Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium*Investigative Ophthalmology & Visual Science, 2008
- Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysisBMJ, 2007
- Contribution of Calpain to Cellular Damage in Human Retinal Pigment Epithelial Cells Cultured with Zinc ChelatorCurrent Eye Research, 2007
- Light Induces Programmed Cell Death by Activating Multiple Independent Proteases in a Cone Photoreceptor Cell LineInvestigative Ophthalmology & Visual Science, 2007
- Age‐related macular degeneration—emerging pathogenetic and therapeutic conceptsAnnals of Medicine, 2006
- CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMDPLOS Medicine, 2005
- A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision LossArchives of Ophthalmology (1950), 2001
- An international classification and grading system for age-related maculopathy and age-related macular degenerationSurvey of Ophthalmology, 1995